Floatz logo

Tislelizumab

Pancreatic Ductal Adenocarcinoma

Daniel Breadnermonoclonal_antibodyPhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
81/ 100

Competitive context

279 Active assets in the Pancreatic Ductal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
OHSU Knight Cancer Institute
Phase 2BB
Daraxonrasib
Revolution Medicines, Inc.
Phase 3BB
Rmc-6236
Tango Therapeutics, Inc.
Phase 3BB
S-1
Genentech, Inc.
Phase 2BB
Xaliplatin
Jonsson Comprehensive Cancer Center
Phase 4BB

View all 50 →

Same molecule, other indications

Tislelizumab is also rated in:

non-small cell lung carcinomaActive
BB
Indicative · Phase 4
69 / 100
View asset →
diffuse large B-cell lymphomaActive
BB
Indicative · Phase 3
67 / 100
View asset →
classic Hodgkin lymphomaActive
BB
Indicative · Phase 3
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →